What You Should Know:
- Medicare has significantly expanded access to the Eversense E3 continuous glucose monitoring (CGM) System, a long-lasting and implantable option that offers several advantages over traditional CGMs.
- Medicare has significantly expanded access to the Eversense E3 CGM System, the longest-lasting continuous glucose monitor available, with the implementation of Local Coverage Determinations providing access to implantable CGM for basal-only patients, by the first three
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
The High Price of Living with Diabetes in 2024: A Breakdown of Costs
What You Should Know:
- The average person with diabetes could spend between $3,300 and $4,600 a year on out-of-pocket costs, including prescription medications, provider visits, over-the-counter supplies, and lost wages, according to a recent GoodRx report.
- The report, The True Cost of Diabetes takes into account medications, visits with healthcare providers, and blood sugar level monitoring, as well as costs for emergency room visits, hospital stays, and chronic complications for those
Read More
Abbott & Tandem Integrate to Bring Automated Insulin Delivery to US
What You Should Know:
- Tandem Diabetes Care and Abbott have joined forces to bring the first automated insulin delivery (AID) system in the US compatible with Abbott's latest FreeStyle Libre 2 Plus sensor.
- The integration brings the benefits of advanced closed-loop technology to millions of Americans living with diabetes, helping them achieve better blood sugar control and manage their condition with greater ease.
Seamless Integration for Precise Control:
The t:slim X2 insulin
Read More
How Hospitals Can Overcome the Challenges of Diabetes Management
The modern-day hospital is grappling with an alarming trend. According to a new global study, the number of people with diabetes is growing at a troubling rate and is expected to double by 2050. This is generating a national conversation among health system leaders on inpatient glycemic management strategies, and whether their facilities are doing enough. Hospitals and health systems have long understood the need to reduce preventable hypoglycemia, yet despite a renewed sense of urgency, many of
Read More
Withings Launches Body Pro 2 for Early Diabetes Detection
What You Should Know:
- Withings Health Solutions has launched Body Pro 2, a revolutionary cellular-connected smart scale that is designed to improve the way patients with diabetes are cared for.
- Body Pro 2 is a cellular-connected smart scale that can be used to capture advanced health metrics such as weight and body composition.
Diabetic Foot Ulcers Assessment
The first module of Body Pro 2 is prescription-only and focuses on improving care for patients with diabetes, addressing
Read More
Prescribing Trends Surge: Wegovy & Ozempic Gain Popularity, Survey Shows
What You Should Know:
- Prescriptions for the popular weight loss drug Wegovy showed a six-fold increase between December 2022 and June 2023, according to a recent analysis of prescribing trends by DrFirst.
- Prescriptions for Ozempic, the lower-dose version for treating diabetes, increased by 65% during the same period among doctors on the DrFirst prescribing network.
- DrFirst's network includes over 350,000 prescribers across the U.S., including 260,000 doctors, who use their
Read More
DaVita, Google Cloud to Develop Customized Clinical OS to Transform Kidney Care
What You Should Know:
- DaVita Inc. and Google Cloud are teaming up to create a new clinical operating system that sets a foundation for streamlined kidney care for more than 200,000 DaVita patients.
- Built on Google Cloud infrastructure and utilizing AI and analytics tools co-developed by the two companies, DaVita's Center Without Walls (CWOW) is now live across the organization's 2,700+ dialysis centers nationwide.
- With the deployment, DaVita has moved from a
Read More
GoodRx Now Offers Access to $35 Insulin to All Americans
What You Should Know:
- GoodRx today announced it is working with Sanofi, a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35.
- This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024. It leverages GoodRx’s reach
Read More
Ozempic: From Diabetes Management to Potential Weight Loss Miracle
You've probably heard about Ozempic, especially if you're one of the millions who regularly scroll through TikTok or browse other social media platforms. It's the drug that influencers are lauding as a revolutionary aid for weight loss, making it a hot topic of conversation.
While Ozempic was initially developed to manage Type 2 diabetes, its emerging potential for weight loss is captivating medical professionals and the public alike.
How Ozempic Works: The Basics
Ozempic is a
Read More
Diabetes Management in 2023 and Beyond: A Tech-Enabled Partnership Between Patient and Doctor
While the pandemic has slowed, there appears to be no end in sight to the diabetes epidemic. The number of individuals diagnosed is projected to keep growing over the next decade. What’s more concerning is that 75% of patients don’t meet guideline-based goals for A1C, blood pressure, and cholesterol control. Uncontrolled diabetes can lead to serious complications like heart disease, kidney failure, blindness, and even amputations.
Thankfully, more patients are embracing technology-based
Read More
